What Are Peptides?

If you've been hearing about peptides lately — in the context of weight loss, healing, anti-aging, or longevity — you're not alone. Peptides have moved from obscure biochemistry into mainstream conversation, driven largely by the success of drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

But the word "peptides" gets used to describe everything from Nobel Prize-winning medicines to unregulated research chemicals sold online. This guide is designed to give you the full picture: what peptides actually are, how they work in your body, and how to think clearly about the different categories of peptide products you'll encounter.

The basics: what is a peptide?

A peptide is a short chain of amino acids linked together by chemical bonds called peptide bonds.^[1] That's the simplest definition. To understand what that means, let's start with the building blocks.

Amino acids, peptides, and proteins

Your body uses 20 standard amino acids as molecular building blocks. Think of them like letters in an alphabet. When you string a few letters together, you get a word. When you string many together, you get a sentence or a paragraph.

The boundary between "peptide" and "protein" isn't rigid — there's no single amino acid count where one becomes the other. In practice, chains of roughly 2 to 50 amino acids are called peptides, and longer chains are called proteins.^[1] But you'll see exceptions: insulin has 51 amino acids and is routinely called a peptide, while some 40-amino-acid chains get called proteins because of how they fold and function.

What about hormones?

This is a common point of confusion. A hormone is not a structural category — it's a functional one. Hormones are chemical messengers that travel through the bloodstream to affect distant organs. Some hormones happen to be peptides (insulin, oxytocin, GLP-1). Others are steroids (testosterone, estrogen, cortisol). Still others are derived from single amino acids (thyroid hormones, adrenaline).

So when someone asks "are peptides hormones?" — the answer is: some are, some aren't. Insulin is both a peptide and a hormone. BPC-157 is a peptide but not a hormone. Testosterone is a hormone but not a peptide.

---

How your body uses peptides

Your body produces thousands of peptides naturally. These endogenous peptides serve as molecular messengers — they carry instructions from one cell to another, or from one organ system to another.^[2]

The analogy that works best: peptides are like molecular keys that fit specific receptor locks on cell surfaces. When the right key finds its lock, it triggers a specific cellular response — releasing another hormone, turning on a gene, or changing how a cell behaves.^[3]

Here are some of the most important peptides your body makes:

Most peptide signaling works through G-protein-coupled receptors (GPCRs) — a large family of receptors embedded in cell membranes. When a peptide binds to its GPCR, it triggers a cascade of signals inside the cell. This is one of the most fundamental communication systems in biology, and GPCRs are the target of roughly 34% of all FDA-approved drugs.^[3]

---

Types of therapeutic peptides

Not all peptide products are the same. They vary enormously in how well they've been studied, how they're made, and what evidence supports their use. Here's how to think about the categories.

Natural peptides used as drugs

These are peptides that exist in your body and have been developed into medicines with minimal modification.

• Insulin — the original peptide drug, first isolated in 1921 by Frederick Banting and Charles Best.^[4] Modern insulin analogs (lispro, glargine, aspart) have been engineered for faster or slower action, but the core molecule is the same one your pancreas makes.
• Oxytocin (Pitocin) — synthetic copy of the natural peptide, used to induce labor and control postpartum bleeding.
• Vasopressin (ADH) — used for diabetes insipidus and critically low blood pressure.
• Calcitonin — used for osteoporosis and hypercalcemia.

Synthetic analogs

These are engineered versions of natural peptides, modified to last longer, work better, or resist degradation.

• Semaglutide (Ozempic, Wegovy, Rybelsus) — a modified version of human GLP-1. The natural GLP-1 peptide is destroyed by enzymes (DPP-4) within about 2 minutes in circulation. Semaglutide has been chemically modified with a fatty acid chain and specific amino acid substitutions that allow it to bind to albumin in the blood, extending its half-life to approximately 7 days.^[5]
• Tirzepatide (Mounjaro, Zepbound) — a chimeric peptide that activates both GLP-1 and GIP receptors simultaneously. It doesn't directly copy either natural peptide — it's engineered to hit both targets at once.^[6]
• Leuprolide (Lupron) — a modified version of GnRH used to treat prostate cancer, endometriosis, and precocious puberty. By continuously stimulating GnRH receptors, it paradoxically shuts them down — a clever pharmacological trick.^[7]

Synthetic fragments

These are pieces of larger natural proteins, synthesized in a lab. The idea is that a specific fragment might retain useful biological activity without needing the full protein.

• BPC-157 — a 15-amino-acid fragment derived from a protective protein found in human gastric juice. Studied extensively in animal models for tissue healing. Has very limited human clinical data.^[8]
• TB-500 — a synthetic fragment of thymosin beta-4 (a 43-amino-acid protein involved in wound healing and cell migration). Important caveat: the full-length thymosin beta-4 has been studied in human clinical trials; the TB-500 fragment sold online has not.^[9]
• AOD-9604 — a fragment of human growth hormone (amino acids 177-191), originally developed for obesity. Failed its pivotal Phase 2b clinical trial in 2007.

Designed-from-scratch peptides

Some therapeutic peptides don't exist in nature at all. They're designed through structure-activity relationship (SAR) studies — systematically testing variations to find molecules with desired properties.

• Ipamorelin — a pentapeptide (5 amino acids) designed as a selective growth hormone secretagogue. It was developed through iterative optimization, not copied from a natural template.^[10]
• Bremelanotide (Vyleesi) — a synthetic melanocortin receptor agonist, developed from research on melanocyte-stimulating hormone pathways. FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women.

---

Why most peptides can't be taken as pills

One of the most common questions: why do most peptides require injection? The answer comes down to biology and chemistry.^[11]

The four barriers to oral peptide delivery

1. Stomach acid. Your stomach maintains a pH of 1-2 — an extremely acidic environment designed to break down food. Most peptides denature (unfold and lose function) in this environment.

2. Digestive enzymes. Your GI tract is full of proteases — enzymes whose entire purpose is to break peptide bonds. Pepsin in the stomach, trypsin and chymotrypsin in the small intestine. These enzymes evolved to dismantle the peptides in your food, and they're very good at it.

3. Poor absorption. Even if a peptide survives the acid and enzymes, it has to cross the intestinal wall to reach the bloodstream. Most peptides are too large and too hydrophilic (water-loving) to pass through the lipid cell membranes that line the intestine.

4. First-pass metabolism. Anything absorbed from the gut travels first to the liver via the portal vein. The liver's job includes breaking down foreign molecules — including peptides — before they reach general circulation.

The combined result: oral bioavailability of most unmodified peptides is less than 1-2%.^[11]

Notable exceptions

Oral semaglutide (Rybelsus) uses a technology called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate). SNAC creates a protective microenvironment around the tablet in the stomach — buffering local pH, shielding semaglutide from pepsin, and temporarily increasing membrane permeability to allow absorption. The effect is transient and fully reversible.^[12]

BPC-157 appears to be unusually acid-stable in preclinical studies — gastric juice doesn't degrade it the way it degrades most peptides. This is part of why oral BPC-157 formulations exist, though no human pharmacokinetic study has confirmed oral bioavailability in people.^[8]

---

Routes of administration

Because oral delivery is so challenging, peptides reach the body through a variety of routes.^[13]

Subcutaneous injection is the most common route for therapeutic peptides, accounting for about 36% of all approved peptide formulations.^[13] It's preferred because it provides reliable absorption, can be self-administered, and avoids the challenges of oral delivery.

If you're new to subcutaneous injection and working with lyophilized (freeze-dried) peptides, see our reconstitution guide for safety-first preparation instructions.

---

The evidence spectrum

This is where honest conversation about peptides matters most. The word "peptide" encompasses both rigorously validated medicines and completely untested research chemicals. Here's how to think about the landscape.

Tier 1: FDA-approved peptide drugs

These have gone through the full regulatory process — preclinical testing, Phase 1/2/3 clinical trials with thousands of participants, and ongoing post-marketing safety surveillance.

These drugs have known safety profiles. Their risks are documented, quantified, and manageable with medical supervision.^[14]

Tier 2: Internationally approved, not in the US

• Thymosin alpha-1 (Zadaxin) — approved in 35+ countries for hepatitis B, hepatitis C, and as an immune adjunct. Over 11,000 subjects studied across 30+ clinical trials. Consistent safety record. Not FDA-approved, but has more human data than most "research peptides" combined.^[15]

Tier 3: Research compounds with some human data

These have been in human studies but haven't completed the full approval process.

• BPC-157 — approximately 30 total human subjects across 3 small studies. No completed randomized controlled trial. A Phase 2 trial for hamstring injury began recruiting in 2026.
• Sermorelin — was briefly FDA-approved for pediatric GH deficiency (Geref), then discontinued in 2008 due to supply issues. Has a well-characterized safety profile from its time as an approved drug.
• CJC-1295 — Phase 1 data showed effective GH stimulation. Phase 2 was terminated after a participant death (attributed to underlying coronary disease, not the drug).
• Ipamorelin — Phase 2 data for GI motility applications. Well-tolerated in studies, but the development program was abandoned.

Tier 4: Research compounds with no human data

• TB-500 fragment — zero registered human clinical trials for the synthetic fragment (distinct from full-length thymosin beta-4, which has been studied in humans).
• KPV — preclinical animal data only. No human safety or efficacy data exists.
• MOTS-c — promising mitochondrial peptide with strong preclinical science. Trials are being registered but none completed.
• Dihexa — no human exposure data per FDA. The foundational research papers have been compromised by image manipulation, with one retracted.

---

---

Regulatory basics

Understanding how peptides are regulated helps you evaluate what you're actually looking at when you encounter a peptide product.

What "FDA-approved" means

When a drug is FDA-approved, it means the manufacturer submitted extensive data from controlled clinical trials demonstrating that the drug is both safe and effective for a specific indication. The FDA reviewed the data, inspected the manufacturing facilities, and determined the benefits outweigh the risks. After approval, the FDA continues to monitor safety through the FAERS adverse event reporting system.^[16]

What "research use only" means (and doesn't mean)

Many peptides sold online carry labels that say "for research use only" or "not for human consumption." This is legally meaningless as a protective disclaimer. The FDA has stated clearly that such labels are a "ruse" used to avoid regulatory scrutiny, and has issued warning letters to companies using them while clearly marketing to consumers for self-administration.^[16]

If a product is sold in a form designed for injection, at doses appropriate for humans, through channels that market to individual consumers — the FDA treats it as an unapproved drug regardless of what the label says.

The Category 1 / Category 2 system

In 2023, the FDA created a classification system for bulk drug substances used in compounding:

• Category 1: Substances that have not been identified as presenting significant safety risks. Compounding pharmacies may use these with a valid prescription under Section 503A of the FD&C Act.
• Category 2: Substances the FDA has determined present potential safety risks. Compounding is effectively prohibited for these substances.

In September 2024, five peptides were removed from Category 2 after their nominators withdrew (AOD-9604, CJC-1295, ipamorelin, thymosin alpha-1, Selank). In February 2026, HHS announced plans to reclassify approximately 14 of the remaining 19 Category 2 peptides to Category 1.^[16]

---

A brief history of peptide therapeutics

Peptide drugs have a longer history than most people realize. Here are the landmarks.^[4][14]

The trajectory is clear: peptide therapeutics have moved from niche to mainstream, with over 80 peptide drugs now FDA-approved and approximately 170 more in active clinical development.^[14]

---

How to evaluate peptide claims

When you encounter a claim about a peptide — whether from a clinic, an influencer, or a vendor — here's a quick framework for evaluating it.

1. What kind of evidence exists?

Ask: has this peptide been studied in humans, or only in animals (or cell cultures)? Results from rats do not reliably predict results in humans. Many promising animal findings fail to replicate when tested in people — in oncology, the translation failure rate exceeds 95%.

Hierarchy of evidence, from strongest to weakest:

• Systematic reviews / meta-analyses of multiple randomized controlled trials
• Randomized controlled trials (RCTs) with adequate sample sizes
• Non-randomized clinical studies (open-label, case series)
• Animal studies (rodents, then larger mammals)
• In vitro studies (cell cultures in a lab)
• Anecdotal reports (forums, testimonials, individual case reports)

2. How many participants, and who funded it?

A study of 12 people without a control group tells you very little. A randomized, placebo-controlled trial of 1,000 people tells you a lot. Also consider who funded the study — industry-funded research isn't automatically invalid, but it's worth noting when the company selling the product also funded the only study showing it works.

3. Has it been replicated?

A single positive study is a signal, not proof. Science advances through replication — independent researchers reproducing results under controlled conditions. If a peptide has only been studied by one research group, the findings should be considered preliminary regardless of how impressive they look.

4. What's the quality of the product?

Even if a peptide has solid clinical evidence, the product you purchase must actually contain the right molecule, at the right dose, without contaminants. Independent testing has found that 43% of gray-market peptides fail to meet purity claims, and up to 23% of some categories contain the wrong molecule entirely. A Certificate of Analysis (COA) from a third-party lab is the minimum standard. See our COA verification guide for details.

5. Is the claim too broad?

Be skeptical of peptides marketed as helping with "everything." Most effective drugs do one or two things well through specific, understood mechanisms. A product claimed to heal tendons, fix gut issues, reduce inflammation, improve brain function, and reverse aging is more likely being marketed on hype than on evidence.

---

Where to go from here

This guide gives you the foundation. Here's where to go deeper:

Related content

Guide

How to Reconstitute Peptides

A safety-first guide to preparing lyophilized peptides. What you need, how to do it, and what to watch for.

Guide

How to Verify a COA

What a Certificate of Analysis should include, what red flags to watch for, and how to check authenticity.

Peptide

Semaglutide

The most-studied peptide therapeutic in history. Full profile covering evidence, safety, and regulatory status.

Peptide

BPC-157

The most-discussed research peptide. An honest look at what the evidence does and doesn't show.

Tool

Reconstitution Calculator

A practical tool for preparing lyophilized peptides — converts vial strength into syringe units.

News

FDA Peptide Categories Explained

How the FDA's Category 1, 2, and 3 system determines which peptides can be compounded.

---

References

1. [1]

   Lopez MJ, Mohiuddin SS. “Biochemistry, Peptide.” StatPearls [Internet]. 2023. PubMedReview

   Continuously updated StatPearls reference covering peptide biochemistry fundamentals.

2. [2]

   Hruby VJ. “Designing peptide receptor agonists and antagonists.” Nature Reviews Drug Discovery. 2002. 1(11):847-858 DOI PubMedReview

   Foundational review of peptide-receptor interactions and structure-activity relationships.

3. [3]

   Foster SR, Hauser AS, Vedel L, Strachan RT, Huang XP, Gaez-Gomez K, et al. “Discovery of human signaling systems: pairing peptides to G protein-coupled receptors.” Cell. 2019. 179(4):895-908 DOI PubMedReview

   Comprehensive mapping of peptide-GPCR signaling systems in humans.

4. [4]

   Vecchio I, Tornali C, Bragazzi NL, Martini M. “The discovery of insulin: an important milestone in the history of medicine.” Frontiers in Endocrinology. 2018. 9:613 DOI PubMedReview

   Historical review of the discovery of insulin and its development as the first peptide drug.

5. [5]

   Drucker DJ. “The GLP-1 journey: from discovery science to therapeutic impact.” Journal of Clinical Investigation. 2024. 134(2):e175634 DOI PubMedReview

   Authoritative review by a leading GLP-1 researcher covering the full history of GLP-1 drug development.

6. [6]

   Gasbjerg LS, Rosenkilde MM, Meier JJ, Nauck MA, Holst JJ. “The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.” Diabetes, Obesity and Metabolism. 2024. 26(Suppl 4):3-13 DOI PubMedReview
7. [7]

   Wilson AC, Mohr DC, Goad J. “Clinical development of the GnRH agonist leuprolide acetate depot.” Journal of Controlled Release. 2023. 357:458-474 DOI PubMedReview

   Comprehensive review of leuprolide development history and long-acting formulation technology.

8. [8]

   Seiwerth S, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, et al. “BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing.” Current Pharmaceutical Design. 2018. 24(18):1972-1989 DOI PubMedReview

   Review by the original BPC-157 research group. Note: most cited studies are from this same group.

9. [9]

   Goldstein AL, Hannappel E, Sosne G, Kleinman HK. “Thymosin beta-4: a multi-functional regenerative peptide. Basic properties and clinical applications.” Expert Opinion on Biological Therapy. 2012. 12(1):37-51 DOI PubMedReview

   Review by Allan Goldstein, discoverer of thymosin beta-4. Covers the full-length protein, not the TB-500 fragment.

10. [10]

    Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. 1998. 139(5):552-561 DOI PubMedReview

    Original characterization of ipamorelin describing its design through structure-activity relationship studies.

11. [11]

    Brayden DJ, Hill TA, Fairlie DP, Maher S, Mrsny RJ. “Systemic delivery of peptides by the oral route: formulation and medicinal chemistry approaches.” Advanced Drug Delivery Reviews. 2020. 157:2-36 DOI PubMedReview

    Comprehensive review of the barriers to oral peptide delivery and current strategies to overcome them.

12. [12]

    Buckley ST, Baekdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahlund J, et al. “Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.” Science Translational Medicine. 2018. 10(467):eaar7047 DOI PubMedReview

    Key paper describing the SNAC absorption enhancer mechanism enabling oral semaglutide.

13. [13]

    Muttenthaler M, King GF, Adams DJ, Alewood PF. “Trends in peptide drug discovery.” Nature Reviews Drug Discovery. 2021. 20(4):309-325 DOI PubMedReview

    Comprehensive review of peptide drug discovery landscape including administration routes and delivery technologies.

14. [14]

    Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, et al. “Therapeutic peptides: current applications and future directions.” Signal Transduction and Targeted Therapy. 2022. 7(1):48 DOI PubMedReview

    Broad review covering the history, current applications, and pipeline of therapeutic peptides.

15. [15]

    Garaci E, Favalli C, Pica F, Sinibaldi Vallebona P, Palamara AT, Matteucci C, et al. “Thymosin alpha 1: from bench to bedside.” Annals of the New York Academy of Sciences. 2007. 1112(1):225-234 DOI PubMedReview

    Review of thymosin alpha-1 clinical development and its approval in 35+ countries outside the US.

16. [16]

    U.S. Food and Drug Administration. “Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.” 2024. Link

    Official FDA guidance on Category 1 and Category 2 bulk drug substances for compounding.

---